<DOC>
	<DOCNO>NCT00704353</DOCNO>
	<brief_summary>The objective study evaluate safety FCM patient anemia dialysis dependent</brief_summary>
	<brief_title>Safety Tolerability Single Dose FCM vs. Standard Care Treating Iron Deficiency Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Subjects ≥18 year age able give inform consent Iron deficiency primary etiology anemia Screening Visit central laboratory Hgb indicative anemia ≤12 g/dL Screening Visit ferritin indicative iron deficiency anemia ≤100 ng/mL ≤300 TSAT ≤30 % Previous participation FCM trial Known hypersensitivity reaction FCM Requires dialysis treatment chronic kidney disease Current anemia attribute iron deficiency Received IV iron , RBC transfusion ( ) , antibiotic 10 day prior screen phase Anticipated need surgery require general anesthesia 30 day prior screen study period AST ALT great 1.5 time upper limit normal Received investigational drug within 30 day screen Pregnant sexuallyactive female able use effective form birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>